FrancophonIA/ELRC3.0 huggingface dataset:
English: This means that documentation provided by the company and formulated lists of questions.
Estonian: Inimravimite komitee oli hinnanud ettevõtte esitatud dokumente ja koostanud ettevõttele vastamiseks küsimused.
English: Afte assessed the company's responses to the last round of questions in an oral explan some unresolved issues.
Estonian: Inimravimite komitee oli ettevõttele esitatud viimaste küsimuste vastused läbi vaadanud, kuid mõni küsimus oli veel lahendamata.
English: The letter from the company notifying the Agency of the withdrawal of the application is available.
Estonian: Ettevõtte kiri, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, on avaldatud jaotises „All documents“.
English: What was Kalbitor exp hereditary angioedema have attacks of swelling that can occur anywhere in face, limbs, gut and throat, causing discomfort and pain and sometimes in the difficulty in breathing.
Estonian: Päriliku angioödeemiga patsientidel esinevad tursehood, mis võivad ilmneda mis tahes kehapiirkonnas, näiteks näol, jäsemetel, soolestikus ja kurgus.
English: l, the CHMP was of the opinion that the benefits of Kalbitor did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ravimi Kalbitor kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: The CHMP had concerns about hypersensitivity reactions, which were see treated with a medicine, and include reactions commonly known as allergic reactions.
Estonian: Ülitundlikkusreaktsioonid tekivad, kui organismi immuunsüsteem töötab ravimi vastu, ja need hõlmavad reaktsioone, mis on üldtuntud kui allergilised reaktsioonid.
English: Based on the review of the data and the company's resp time of the withdrawal, the CHMP had some concerns and was of the provisional o could not have be
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatuseks ja oli esialgsel seisukohal, et ravimi Kalbitor kasutamist ei ole võimalik heaks kiita.
English: Kalbitor was expected to be used to treat symptoms of attacks of hereditary angioedema.
Estonian: Kalbitori kavatseti kasutada päriliku angioödeemi hoogude sümptomite raviks.
English: The effects of Kalbitor were first tested in experimental models before being studie The company presented the results of two main studies in patients aged 1 hereditary angioedema.
Estonian: Ettevõte esitas kahe peamise uuringu tulemused, milles osalesid 10-aastased ja vanemad päriliku angioödeemiga patsiendid.
English: The active substance in Kalbitor, ecallantide, blocks an enzyme in the blood called ‘kallikrein'.
Estonian: Kalbitori toimeaine ekallantiid blokeerib veres sisalduva ensüümi kallikreiini.
English: 011, Dyax s.a. officially notified the Committee for Medicinal Products for Human ation for Kalbitor, treatment of symptoms of acute attacks of hereditary angioedema.
Estonian: Dyax s.a. teatas 11. novembril 2011 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Kalbitor müügiloa taotlus.
English: he actions of kallikrein, Kalbitor is lantide in Kalbitor is produced by a method known as ‘recombinant DNA technology'.
Estonian: Kalbitoris sisalduv ekallantiid valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud ekallantiini tekkimist võimaldav geen (DNA).
English: What were the reasons given by the company for withdrawing the
Estonian: Mis põhjustel võttis ettevõte taotluse tagasi?
English: Kallikrein is part of a complex network of proteins (known as the kallikrein-kinin system) that has several effects in the body, one of which results in increased levels of a protein called bradykinin that causes the blood vessels to widen and leak fluid into the surrounding tissue.
Estonian: Kallikreiin on osa keerukast valkude võrgustikust (tuntud kui kallikreiini-kiniini süsteem), millel on organismis mitmed toimed.
English: ents' symptoms after four he evaluation was the application when it was withdrawn?
Estonian: Mis järgus oli müügiloa taotluse hindamine, kui see tagasi võeti?
English: By blocking t expected to help reduce the swelling and related symptoms of angioedema.
Estonian: Arvatakse, et kallikreiini toimeid blokeerides aitab Kalbitor vähendada turset ja sellega seotud angioödeemi sümptomeid.
English: There were 72 patients in one study and 96 in the other treated with either Kalbitor or placebo (a dummy treatment) w judged to be at risk of blockage of the airway were given additional treatments i The main measure of effectiveness was based on the improvement in pati hours.
Estonian: Patsiente raviti 8 tunni jooksul pärast hoo algust kas Kalbitori või platseeboga (näiv ravim).
English: Hypersensitivity reactions occur when the body's immune system reacts against MP also had concerns related to the effectiveness of the proposed doses in heavier patients.
Estonian: Inimravimite komiteel oli kahtlusi ka seoses väljapakutud annuste efektiivsusega suurema kehakaaluga patsientidel.
English: Withdrawal of the marketing authorisation application for
Estonian: Teave müügiloa taotluse tagasivõtmise kohta: Kalbitor (ekallantiid)
English: available as a solution for injection.
Estonian: Seda kavatseti turustada süstelahusena.
English: the CHMP had evaluated the r the CHMP had ation, there were still onse to the CHMP lists of questions, at the pinion that Kalbitor en approved.
Estonian: Inimravimite komitee väljendas ettevaatlikkust ülitundlikkusreaktsioonide pärast, mida täheldati Kalbitoriga ravitud patsientidel sagedamini.
English: Pack size
Estonian: Abiained
English: Immediate Packaging
Estonian: Seedetrakti häired
English: 28 vials + 28 prefilled syringes; 6 plungers
Estonian: Pakendis olevad materjalid: - 28 viaali 1,25 mg teduglutiidi pulbriga - 28 eeltäidetud süstalt lahustiga
English: 28 vials + 28 prefilled syringes
Estonian: Pakendis on 28 viaali pulbriga koos 28 eeltäidetud süstlaga.
English: Strength Pharmaceutical Form Route of Administration
Estonian: RAVIMVORM JA PAKENDI SUURUS
English: Content (concentration)
Estonian: TOIMEAINE(TE) SISALDUS
English: MA (EU) number (Invented) name
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/12/787/001
English: 1 vial + 1 prefilled syringe
Estonian: Revestive 5 mg süstelahuse pulber ja lahusti Teduglutiid
English: • Circulation, within 25 days of the Commission Decision, of the adopted Dear Healthcare Professional Communication as specified in the communication plan
Estonian: • 25 päeva jooksul pärast komisjoni otsuse vastuvõtmist saadetakse laiali teavitamiskavas märgitud tervishoiutöötajate teatis.
English: Annex IV Conditions of the Marketing Authorisation
Estonian: IV lisa Müügiloa tingimused
English: National Competent Authorities shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Estonian: Riiklikud pädevad asutused tagavad, et müügiloa hoidjad täidavad järgmised tingimused:
English: one type I glass bottle of lyophilisate and one type I glass bottle of solvent, 1 syringe and 1 needle
Estonian: üks I tüüpi klaasist viaal lüofilisaadiga ja üks I tüüpi klaasist viaal lahustiga, 1 süstal ja 1 nõel
English: These studies are still ongoing.
Estonian: Uuringud veel kestavad.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Humenza to Sanofi Pasteur SA on 08 June 2010.
Estonian: Euroopa Komisjon andis Humenza müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Sanofi Pasteur SA 8. juunil 2010.
English: This second dose must be given to patients over 60 years of age.
Estonian: Seda peab manustama üle 60-aastastele patsientidele.
English: A second dose may be given after an interval of at least three weeks, particularly in children from six months to three years of age.
Estonian: Teise annuse võib manustada vähemalt kolme nädala pärast, eelkõige 6 kuu kuni 3 aasta vanustele lastele.
English: Humenza is given according to official recommendations.
Estonian: Humenzat määratakse vastavalt ametlikele juhistele.
English: This means that there is more evidence to come about the medicine, in particular the results of further clinical studies in children, adolescents and adults.
Estonian: See tähendab, et vaktsiini kohta oodatakse veel andmeid, eelkõige lastel, noorukitel ja täiskasvanutel tehtavate täiendavate kliiniliste uuringute tulemusi.
English: It should only be used for the influenza A (H1N1) flu pandemic that was officially declared by the World Health Organization on 11 June 2009.
Estonian: Seda tohib kasutada ainult 11. juunil 2009 Maailma Terviseorganisatsiooni ametlikult välja kuulutatud A (H1N1)-gripi pandeemia korral.
English: Which measures are being taken to ensure the safe use of Humenza?
Estonian: Mis meetmeid võetakse, et tagada Humenza kasutamise ohutus?
English: Three studies are being carried out with Humenza containing the H1N1 strain, one in 300 adults and 150 elderly patients (over 60 years of age), and two in a total of 700 children aged between six months and 17 years of age.
Estonian: H1N1-tüve sisaldavat Humenzat uuriti kolmes uuringus: ühes osales 300 täiskasvanud ja 150 eakat (üle 60-aastast) patsienti ja kahes teises uuringus osales kokku 700 last vanuses 6 kuud kuni 17 aastat.
English: Preliminary results from the three ongoing studies show that one dose of Humenza was able to trigger immunity to a satisfactory level in adults and children.
Estonian: Kolme toimuva uuringu esialgsetest tulemustest nähtub, et 1 annus Humenzat tekitas täiskasvanutel ja lastel rahuldava tasemega immuunsuse.
English: This will include information on its side effects and its safety in children, the elderly, pregnant women, patients with severe conditions and people who have problems with their immune systems.
Estonian: See hõlmab kõrvalnähtude andmeid ja ohutusteavet seoses kasutamisega lastel, eakatel, rasedatel, raskes seisundis ja immuunsüsteemi häiretega patsientidel.
English: However, it may be appropriate to give the vaccine to these patients during a pandemic, as long as facilities for resuscitation are available.
Estonian: Pandeemia ajal võib olla vaja manustada vaktsiini ka neile patsientidele, kui on võimalik kasutada elustamisvõimalusi.
English: Humenza contains a flu strain called A/California/7/2009 (H1N1)-like strain (NYMC X-179A).
Estonian: Humenza sisaldab gripiviiruse tüvele A/California/7/2009 (H1N1) sarnast tüve (NYMC X-179A).
English: Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
Estonian: Pandeemilise gripi vaktsiin (H1N1) (inaktiveeritud purustatud viirus, adjuveeritud)
English: This document is a summary of the European Public Assessment Report (EPAR) for Humenza.
Estonian: Käesolev dokument on vaktsiini Humenza Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Humenza:
Estonian: Muu teave Humenza kohta
English: The company that makes Humenza will collect information on the safety of the vaccine while it is being used.
Estonian: Humenza tootja kogub teavet vaktsiini ohutuse kohta selle kasutamise ajal.
English: Humenza should not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace levels in the vaccine, such as ovalbumin (a protein in egg white), egg or chicken proteins, neomycin, octoxinol-9 and formaldehyde.
Estonian: Humenzat ei tohi manustada patsientidele, kellel on tekkinud anafülaktiline reaktsioon (raske allergiline reaktsioon) vaktsiini mis tahes koostisosa või aine suhtes, mida vaktsiin mikrokogustes sisaldab, näiteks ovalbumiin (munavalge valk), muna- või kanavalgud, neomütsiin, oktoksinool-9 ja formaldehüüd.
English: The company also presented information from studies in 641 adults carried out using an earlier version of Humenza, containing a ‘bird flu' strain H5N1.
Estonian: Ettevõte esitas ka uuringu (641 patsienti) andmed, milles kasutati Humenza varasemat, linnugripiviiruse tüve H5N1 sisaldavat varianti.
English: The percentage of subjects who had a level of antibodies in their blood that was high enough to neutralise the H1N1 virus (seroprotection rate) was 100% in children and close to 100% in adults.
Estonian: Neid patsiente, kelle veres tekkis H1N1-viiruse neutraliseerimiseks piisav antikehade sisaldus veres, oli lastest 100% ja täiskasvanutest ligikaudu 100%.
English: The most common side effects with Humenza (seen with more than 1 in 10 doses of the vaccine) are headache, myalgia (muscle pain) and pain at the site of injection.
Estonian: Humenza kõige sagedamad kõrvalnähud (esinenud enam kui 1 vaktsiiniannuse korral 10st) on peavalu, müalgia (lihasevalu) ja valu süstekohal.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Humenza.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas vaktsiini ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas vaktsiini kasutada.
English: The company that makes Humenza will supply further data on the medicine, in particular on its safety from a study in 3,000 subjects.
Estonian: Humenza tootja esitab vaktsiini kohta lisaandmed, eelkõige vaktsiini ohutuse kohta 3000 isikuga uuringust.
English: The Committee decided that Humenza's benefits are greater than its risks for the prophylaxis of influenza in the officially declared H1N1 pandemic situation and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Humenza kasulikkus on gripi ennetamisel ametlikult välja kuulutatud H1N1pandeemia korral suurem kui sellega kaasnevad riskid.
English: What information is still awaited for Humenza?
Estonian: Mis andmeid Humenza kohta veel oodatakse?
English: Humenza is a vaccine to protect against ‘pandemic' flu.
Estonian: Humenza on vaktsiin, mida kasutatakse pandeemilise gripi eest kaitsmiseks.
English: These studies are looking at the ability of Humenza to trigger the production of antibodies (‘immunogenicity') against the H1N1 flu strain.
Estonian: Uuringutes uuriti Humenza võimet stimuleerida gripiviiruse tüve H1N1 vastaste antikehade (immunogeensuse) teket.
English: For the full list of all side effects reported with Humenza, see the Package Leaflet.
Estonian: Humenza kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Humenza is a vaccine.
Estonian: Humenza on vaktsiin.
English: What is Humenza?
Estonian: Mis on Humenza?
English: Why has Humenza been approved?
Estonian: Miks Humenza heaks kiideti?
English: What is the risk associated with Humenza?
Estonian: Mis riskid Humenzaga kaasnevad?
English: Humenza has been given ‘Conditional Approval'.
Estonian: Humenzale anti müügiluba tingimuslikult.
English: The seroprotection rates in elderly subjects were lower but a second dose was shown to bring about a further response.
Estonian: Piisava antikehade sisaldusega eakaid patsiente oli vähem, kuid teise annuse järel nende arv suurenes.
English: Humenza is given as one dose, injected into the upper arm or thigh muscle.
Estonian: Humenzat manustatakse ühe annusena, süstena õlavarre või reie lihasesse.
English: Humenza contains small amounts of haemagglutinins (proteins from the surface) of a virus called A(H1N1)v that is causing the current pandemic.
Estonian: Humenza sisaldab vähesel hulgal praegust pandeemiat põhjustava viiruse A(H1N1)v hemaglutiniine (viiruse pinnavalgud).
English: How does Humenza work?
Estonian: Kuidas Humenza toimib?
English: How is Humenza used?
Estonian: Kuidas Humenzat kasutatakse?
English: The full EPAR for Humenza can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Humenza kohta on siin.
English: The vaccine can only be obtained with a prescription.
Estonian: Vaktsiin on retseptiravim.
English: What benefit has Humenza shown during the studies?
Estonian: Milles seisneb uuringute põhjal Humenza kasulikkus?
English: What is Humenza used for?
Estonian: Milleks Humenzat kasutatakse?
English: How has Humenza been studied?
Estonian: Kuidas Humenzat uuriti?
English: Humenza is a vaccine that is given by injection.
Estonian: Humenza on süstitav vaktsiin.
English: Do not smoke, drink or eat whilst handling.
Estonian: Ärge suitsetage, jooge ega sööge toote käsitsemise ajal.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 06/05/2011.
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 06/05/2011
English: Fipronil: Absolute bioavailability: 9.5 %.
Estonian: Fiproniil: absoluutne biosaadavus on 9,5 %.
English: 29, avenue Tony Garnier FR-69007 Lyon France.
Estonian: 29, avenue Tony Garnier FR-69007 Lyon Prantsusmaa.
English: For this reason the transmission of infectious diseases cannot be completely excluded if conditions are unfavourable.
Estonian: Seepärast ei saa ebasoodsate tingimuste korral nakkushaiguste ülekandumist täielikult välistada.
English: Children should not be allowed to play with treated dogs until the application site is dry.
Estonian: Lastel ei tohiks lasta ravi saanud koertega mängida, kuni ravimi pealekandmise koht on kuiv.
English: Distribution, metabolism, and excretion
Estonian: Jaotumine, metabolism ja eritumine
English: For dogs over 60 kg, use the appropriate combination of two pipettes that most closely matches the bodyweight.
Estonian: Üle 60 kg koerte puhul kasutage sobivat kahe pipeti kombinatsiooni, mis vastaks kõige ligilähedasemalt koera kaalule.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt aadressil http://www.ema.europa.eu
English: The CVMP at their meeting on 18 February 2016 decided that one additional five-year renewal was required in view of the outstanding pharmacovigilance data that were undergoing evaluation at the time of the renewal procedure and to ensure that the MAH's pharmacovigilance system is adequate to enable collection and evaluation of adverse events in line with the requirements.
Estonian: Veterinaarravimite komitee otsustas oma koosolekul 18. veebruaril 2016, et on vajalik veel üks viie aasta pikkune lisaperiood uuendusperioodil jooksul ette tulnud oluliste ravimiohutuse andmete hindamise tõttu, ning peab tagama, et müügiloa hoidja ravimiohutuse süsteem oleks piisav, et võimaldada nõuetekohane kõrvalekallete kogumine ja hindamine.
English: CERTIFECT should not enter water courses as this may be dangerous for fish and aquatic organisms.
Estonian: CERTIFECT ei tohi sattuda veekogudesse, kuna see võib ohtlik olla kaladele ja veeorganismidele.
English: The use of protective gloves is recommended.
Estonian: Soovitatav on kanda kaitsekindaid.
English: Elimination of fleas and ticks within 24 hours.
Estonian: Kirpude ja puukide kõrvaldamine 24 tunni jooksul.
English: (S)-Methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials.
Estonian: (S)-metopreen degradeerub ulatuslikult süsinikdioksiidiks ja atsetaadiks, mis liidetakse seejärel endogeensete materjalidega.
English: In very rare instances, certain sensitive dogs may develop skin irritation at the application site.
Estonian: Väga harvadel juhtudel võib mõnedel tundlikel koertel tekkida nahaärritus manustamiskohas.
English: Major metabolites are distributed over the entire haircoat of the dog.
Estonian: Peamised metaboliidid jaotuvad üle kogu koera karvkatte.
English: In these cases do not treat more frequently than once a fortnight.
Estonian: Sellistel juhtudel ärge kasutage ravimit sagedamini kui kord kahe nädala järel.
English: It is therefore recommended that dogs are not treated during the day, but during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children.
Estonian: Seega ei ole soovitatav ravida koeri päevasel ajal, vaid õhtupoolikul, ja äsja ravitud loomadel ei tohiks lasta omanike, eriti laste voodis magada.
English: Monthly intervals throughout the tick and/or flea seasons, based on local epidemiological situations.
Estonian: Kuuajalised intervallid kogu puugi- ja/või kirbuhooaja vältel vastavalt kohalikule epidemioloogilisele
English: However the attachment of single ticks after treatment cannot be excluded.
Estonian: Samas ei saa välistada üksikute puukide kinnitumist pärast ravi.
English: Systemic absorption of CERTIFECT is low for all three active substances following topical administration.
Estonian: CERTIFECT-i süsteemne imendumine on pärast paikset manustamist kõigi kolme toimeaine puhul madal.
English: The treated area may appear wet or oily after treatment.
Estonian: Ravitud piirkond võib pärast ravimi pealekandmist märg või õline tunduda.
English: Dogs should be prevented from accessing streams and rivers for 48-hours following treatment (see section 6.6).
Estonian: Koeri ei tohiks 48 tunni jooksul pärast ravi ojade ja jõgede äärde lasta (vt lõik 6.6).
English: This veterinary medicinal product may cause skin sensitisation, allergic reactions and mild eye irritation in humans.
Estonian: Antud veterinaarravim võib põhjustada inimestel naha tundlikkust, allergilisi reaktsioone ja kerget silmade ärritust.
English: One treatment prevents further infestations for 5 weeks by ticks and for up to 5 weeks by fleas.
Estonian: Üks ravikord ennetab edasisi infestatsioone puukide puhul 5 nädala ja kirpude puhul kuni 5 nädala vältel.
English: The secondary packaging consists of a plastic/ aluminium blister with a plastic/ aluminium backing.
Estonian: Välispakend koosneb plast-/alumiiniumblisterist, millel on plastist/alumiiniumist tagaosa.
English: If symptoms are severe or persist alternatively use antidote (atipamezole hydrochloride).
Estonian: Kui sümptomid on tõsised või püsivad, siis kasutage antidooti (atipamesoolhüdrokloriidi).
English: Fipronil's major metabolite on the haircoat of the dog and in the blood stream is the sulfone derivative.
Estonian: Aine fiproniil peamine metaboliit koera karvkattes ja vereringes on sulfooni derivaat.
English: In case of massive flea infestation and at the beginning of the control measures these areas should be treated with a suitable environmental product and then vacuumed regularly.
Estonian: Ulatusliku kirpudega nakatumise korral ja kirbutõrjet alustades tuleks neid piirkondi sobiva keskkonnale mõeldud tootega töödelda ning seejärel regulaarselt tolmuimejaga puhastada.
English: Fipronil sulfone is produced on the haircoat (mean concentrations < 16 % of fipronil during the first month after treatment).
Estonian: Fiproniilsulfooni produtseeritakse karvkattel (aine Fiproniil keskmised kontsentratsioonid esimese ravijärgse kuu jooksul on < 16 %).
English: Detailed information on this product is available on the website of the European Medicines Agency
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt aadressil
English: Treated animals should not be bathed until 48 hours after treatment.
Estonian: Ravi saanud loomi ei tohiks kuni 48 tundi pärast ravimi kasutamist vannitada.
English: (S)-Methoprene and Amitraz: Dermal absorption is very low and all plasma concentrations were below the limit of quantification (10 ng/ml) for (S)-methoprene and were undetectable for amitraz (< 0.75 ng/ml) in most samples.
Estonian: (S)-methopreen ja amitraas: nahakaudne imendumine on väga madal ja kõik plasmakontsentratsioonid jäid enamikes proovides aine (S)-metopreen puhul alla kvantifitseerimispiiri (10 ng/ml) ning olid aine amitraas puhul tuvastamatud (< 0,75 ng/ml).
English: The concentrations of fipronil, fipronil sulfone, amitraz and S-methoprene in the haircoat then decrease with time and are detectable for at least 58 days after dosing.
Estonian: Ainete fiproniil, fiproniilsulfoon, amitraas ja (S)-metopreen kontsentratsioonid hakkavad seejärel aja jooksul karvkattes vähenema ning on tuvastatavad vähemalt 58 päeva pärast annustamist.
English: PACKAGE LEAFLET FOR (Card of 1 pipette)
Estonian: PAKENDI INFOLEHT (1 pipetiga kaart)